i2o Ther­a­peu­tics clos­es $46M Se­ries A, names Kurt Graves as CEO and ac­quires Intar­cia’s twice-re­ject­ed di­a­betes as­set

In a slew of com­pa­ny up­dates, i2o Ther­a­peu­tics has closed a Se­ries A raise worth $46 mil­lion from biotech in­vestors and named Kurt Graves as its new chair­man, pres­i­dent and CEO.

The biotech al­so ac­quired the car­diometa­bol­ic clin­i­cal pipeline of Intar­cia Ther­a­peu­tics, which has six can­di­dates, in­clud­ing IT­CA 650 — a type 2 di­a­betes drug/de­vice com­bo which has been re­ject­ed by the FDA twice. The oth­er five as­sets are all in the pre­clin­i­cal stage un­der con­sid­er­a­tion for T2D, non­al­co­holic steato­hep­ati­tis and obe­si­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER